Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Tolterodine for Overactive Bladder
The Medical Letter 40:101-102, , 1998
Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter 39:61-62, , 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Frequency of AQP4 and MOG Antibodies in Patients with Optic Neuritis Fulfilling Minimal New Multiple Sclerosis MRI Criteria
Neurol 106:e214753, Deschamps,R.,et al, 2026
Differentiating Multiple Sclerosis from AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease with Imaging
Neurol 100:e308-e323, Cortesa,R.,et al, 2023
Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder
Neurol 100:e1418-e1432, Cacciaguerra, L.,et al, 2023
Initial Highly Effective Therapy for MS
Neurol 95:1114-1116, Wallin, M.T., 2020
"Better Explanations" in Multiple Sclerosis Diagnostic Workup
Neurol 92:e2527-e2537, Calabrese, M.,et al, 2019
Vaccine-Preventable Infections and Immunization in Multiple Sclerosis
Neurol 93:584-594, Farez, M.F.,et al, 2019
Evaluation of Idiopathic Transverse Myelitis Revealing Specific Myelopathy Diagnoses
Neurol 90:e96-102, Zalewski, N.L.,et al, 2018
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Value of the Central Vein Sign at 3T to Differentiate MS from Seropositive NMOSD
Neurol 90:e1183-e1190, Cortese, R.,et al, 2018
Misdiagnosis of Multiple Sclerosis
Neurol 92:15-16, Brownlee, W.J., 2018
Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Acute Idiopathic Transverse Myelitis in Children
Neurol 84:341-349,332, Deiva, K.,et al, 2015
Summary of Evidence-Based Guideline: Complementary and Alternative Medicine in Multiple Sclerosis
Neurol 82:1083-1092, Yadav, V.,et al, 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Longitudinally Extensive Transverse Myelitis with and Without Aquaporin 4 Antibodies
JAMA Neurol 70:1375-1381, Kitley, J.,et al, 2013
Distinct Lesion Morphology at 7-T MRI Differentiates Neuromyelitis Optica from Multiple Sclerosis
Neurol 79:708-714, Sinnecker, T.,et al, 2012
The Differential Diagnosis of Longitudinally Extensive Transverse Myelitis
Mult Scler 18:271-285, Kitley, J.L.,et al, 2012
Optic Neuritis: Prognosis and Treatment
UpToDate, Jan, Osborne, B.,et al, 2011
Longitudinally Extensive Myelopathy in Caucasians: A West Australian Study of 26 Cases from the Perth Demyelinating Diseases Database
JNNP 81:209-212, Qiu,W.,et al, 2010
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Pregnancy and Fetal Outcomes After Interferon-b Exposure in Multiple Sclerosis
Neurol 75:1794-1802, Amato,M.P.,et al, 2010
Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study
Arch Neurol 66:1345-1352, Moraal,B.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Picturing Multiple Sclerosis: Conventional and Diffusion Tensor Imaging
Semin Neurol 28:453-466, Fox,R.J., 2008
Non-Communicating Syringomyelia: A Feature of Spinal Cord Involvement in Multiple Sclerosis
Brain 131:1776-1782, Weier,K.,et al, 2008
An Approach to the Diagnosis of Acute Transverse Myelitis
Semin Neurol 28:105-120, Jacob, A.,et al, 2008
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007